Novo Integrated Sciences Reports Fiscal Year 2024 First Quarter Financial Results

Rhea-AI Summary

Novo Integrated Sciences, Inc. (NVOS) reported financial results for the first fiscal quarter ended November 30, 2023, with a focus on commercializing proprietary product offerings and essential services. They also announced pending non-traditional financing opportunities and achieved an increase in revenue. The company's total assets, liabilities, and stockholders' equity were disclosed, along with revenue and operating costs. Corporate and operational highlights included a reverse stock split, an agreement to purchase the Ophir Collection, and regaining compliance with Nasdaq's minimum bid price requirement.

Insights

Financial Analyst

Novo Integrated Sciences, Inc.'s financial results indicate a complex strategy for managing capital and revenue growth. The reported increase in revenue by 14% is a positive sign, but this is overshadowed by the 32% spike in operating costs, leading to a 19% rise in net loss. The issuance of common stock for services and cashless warrant exercises as part of operating expenses is an unconventional approach, which could dilute shareholder value over time. However, the company's efforts to secure non-dilutive financing, such as the $70 million debt instrument and monetization of the Ophir Collection, are attempts to balance capital needs without further diluting equity. The 1-for-10 reverse stock split suggests a strategic move to prop up the stock price and maintain compliance with Nasdaq's minimum bid price requirement, which they have achieved. Investors should consider the implications of the company's financing strategies on long-term financial stability and shareholder value.

Market Research Analyst

Novo's holistic approach to healthcare, integrating product sales with healthcare services, reflects an emerging trend in the industry to create a more comprehensive patient experience. The slight increase in healthcare services revenue, despite a more significant overall revenue increase, suggests that product sales are currently driving growth more than service expansion. This could indicate a strategic pivot or a diversification of revenue streams, which may be appealing to investors looking for companies innovating within the healthcare sector. Additionally, the company's ability to regain compliance with Nasdaq's listing requirements may instill renewed confidence in the market. However, the reliance on non-traditional financing and asset monetization, such as the Ophir Collection, is atypical for a healthcare company and could introduce unique risks and volatility to the stock.

Economist

Novo Integrated Sciences' financial maneuvers, including a mix of debt financing and asset monetization, come at a time when capital markets are tight and traditional financing may be more expensive. The choice of non-traditional financing could be seen as an adaptive response to the current economic climate. The company's access to foundational capital through these means could enable continued investment in their three-pillar business model, which is crucial for long-term growth. However, the increase in operating costs and net loss is concerning and raises questions about the efficiency of their operational management. The economic implications of these financial strategies will depend on the company's ability to effectively leverage the acquired capital for growth and to manage the repayment terms without compromising their financial health.

BELLEVUE, Wash.--(BUSINESS WIRE)-- Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, today reported its financial results for the first fiscal quarter ended November 30, 2023.

Robert Mattacchione, Novo’s CEO and Board Chairman, stated, “The Company remains committed to the commercialization of its proprietary product offerings and the expansion and delivery of its essential services and solutions for how non-catastrophic healthcare is delivered both now and in the future. During the fiscal year 2024 first quarter period, the Company continued to work with certain prospective financial partners to close previously announced non-traditional financing opportunities for the Company’s business capital needs, including (i) an unsecured, non-dilutive 15-year debt instrument, with a principal sum of $70,000,000, which provides for net proceeds to the Company of approximately $52,000,000, after fees; (ii) the acquisition and monetization of the Ophir collection, a certain collection of 43 gemstones, 42 of which are certified by the Gemological Institute of America (the “Ophir Collection”); and (iii) a collateral transfer agreement of a One Billion Dollar gold-backed bond for the purpose and general use of monetization by Novo for a period of up to 15 years. In today’s environment of tight capital markets and expensive capital raises, these pending transactions would allow the Company access to the foundational capital and repayment terms necessary to support and accelerate the further implementation and growth of Novo’s three-pillar business model.”

Financial Highlights for the three month period ended November 30, 2023:

• Cash and cash equivalents were $1,640,007, total assets were $37,244,384, total liabilities were $13,960,336, and stockholders’ equity was $23,284,048.
• Revenues were $3,891,218, representing an increase of $471,938, or 14%, from $3,419,280 for the same period in 2022. The increase in revenue was principally due to an increase in product sales. Acenzia’s and Terragenx’s revenue for the three months ended November 30, 2023 were $1,683,850 and $16,971, respectively. Revenue from our healthcare services increased by 1.2% when comparing the revenue for the same period in 2022.
• Operating costs were $5,261,655, representing an increase of $1,280,162, or 32%, from $3,981,493 for the same period in 2022. The increase in operating costs was principally due to common stock issuance for services and cashless warrant exercise.
• Net loss attributed to the Company was $4,680,343, representing an increase of $744,930, or 19%, from $3,935,413 for the same period in 2022. The increase in net loss was principally due to the increase in operating expenses.
• On September 12, 2023, the Company issued a $3,500,000 promissory note (12% per annum interest rate) with a purchase price of $3,150,000 and completed the related Securities Purchase Agreement with Mast Hill Fund, L.P. (“Mast Hill”). No warrants or shares were issued under the terms and conditions of this transaction with Mast Hill.
• On September 18, 2023, the Company issued a $277,778 promissory note (12% per annum interest rate) with a purchase price of $250,000 and completed the related Securities Purchase Agreement with FirstFire Global Opportunities Fund, LLC (“FirstFire”). No warrants or shares were issued under the terms and conditions of this transaction with FirstFire.
• On September 21, 2023, the total principal and interest of $577,521 owed on the $573,000 FirstFire promissory note, dated March 21, 2023, was converted to 519,845 restricted shares of the Company’s common stock and paid in full.

Corporate and Operational Highlights for the three month period ended November 30, 2023:

• On November 6, 2023, the Company effectuated a 1-for-10 reverse stock split (the “Reverse Stock Split”). The Company’s common stock began trading on the Nasdaq Capital Market on a Reverse Stock Split-adjusted basis on November 7, 2023.
• On November 21, 2023, the Company entered into a Purchase and Sale Agreement (“Ophir Agreement”) between the Company and Blake Alsbrook, solely in his capacity as Court-appointed successor receiver (the “Successor Receiver”) in Ocean Thermal Energy Corporation v. C. Robert Coe II, et al., United States District Court for the Central District of California (the “Court”) Case No. 2:19-cv-04299 VAP (JPRx). Pursuant to the terms of the Ophir Agreement, the Company agreed to purchase, and the Successor Receiver agreed to sell to the Company, the Ophir Collection, subject to the contingencies outlined in the Ophir Agreement, including Court approval, which was received on December 1, 2023. All parties involved in this Ophir Agreement continue to work toward closing the transactions contemplated by the Ophir Agreement. Upon closing of the acquisition of the Ophir Collection, the Company intends to monetize the Ophir Collection.
• On November 22, 2023, the Company received notice from The Nasdaq Stock Market, LLC (“Nasdaq”) informing the Company that it had regained compliance with the minimum bid price requirement as set forth under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market.

About Novo Integrated Sciences, Inc.

Novo Integrated Sciences, Inc. is pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation. Novo offers an essential and differentiated solution to deliver, or intend to deliver, these services and products through the integration of medical technology, advanced therapeutics, and rehabilitative science.

We believe that “decentralizing” healthcare, through the integration of medical technology and interconnectivity, is an essential solution to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered both now and in the future. Specific to non-critical care, ongoing advancements in both medical technology and inter-connectivity are allowing for a shift of the patient/practitioner relationship to the patient’s home and away from on-site visits to primary medical centers with mass-services. This acceleration of “ease-of-access” in the patient/practitioner interaction for non-critical care diagnosis and subsequent treatment minimizes the degradation of non-critical health conditions to critical conditions as well as allowing for more cost-effective healthcare distribution.

The Company’s decentralized healthcare business model is centered on three primary pillars to best support the transformation of non-catastrophic healthcare delivery to patients and consumers:

• First Pillar: Service Networks. Deliver multidisciplinary primary care services through (i) an affiliate network of clinic facilities, (ii) small and micro footprint sized clinic facilities primarily located within the footprint of box-store commercial enterprises, (iii) clinic facilities operated through a franchise relationship with the Company, and (iv) corporate operated clinic facilities.
• Second Pillar: Technology. Develop, deploy, and integrate sophisticated interconnected technology, interfacing the patient to the healthcare practitioner thus expanding the reach and availability of the Company’s services, beyond the traditional clinic location, to geographic areas not readily providing advanced, peripheral based healthcare services, including the patient’s home.
• Third Pillar: Products. Develop and distribute effective, personalized health and wellness product solutions allowing for the customization of patient preventative care remedies and ultimately a healthier population. The Company’s science-first approach to product innovation further emphasizes our mandate to create and provide over-the-counter preventative and maintenance care solutions.

Innovation through science combined with the integration of sophisticated, secure technology assures Novo Integrated Sciences of continued cutting-edge advancement in patient-first platforms.

For more information concerning Novo Integrated Sciences, please visit www.novointegrated.com.

Twitter, LinkedIn, Facebook, Instagram, YouTube

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts included in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by words such as "believe," “intend,” "expect," "anticipate," "plan," "potential," "continue" or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks and uncertainties are discussed in Novo’s filings with the Securities and Exchange Commission. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond Novo’s control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects Novo’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Novo assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The contents of any website referenced in this press release are not incorporated by reference herein.

NOVO INTEGRATED SCIENCES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
As of November 30, 2023 (unaudited) and August 31, 2023
		November 30,				August 31,
		2023				2023
ASSETS
Current Assets:
Cash and cash equivalents		$	1,640,007			$	416,323
Accounts receivable, net			2,636,174				1,467,028
Inventory, net			1,270,835				1,106,983
Other receivables			1,047,742				1,051,584
Prepaid expenses and other current assets			213,812				346,171
Total current assets			6,808,570				4,388,089
Property and equipment, net			5,306,613				5,390,038
Intangible assets, net			15,704,218				16,218,539
Right-of-use assets, net			1,870,204				1,983,898
Goodwill			7,554,779				7,582,483
TOTAL ASSETS		$	37,244,384			$	35,563,047
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts payable		$	3,403,634			$	3,513,842
Accrued expenses			1,300,549				1,233,549
Accrued interest (including amounts to related parties)			480,719				382,666
Government loans and notes payable, current portion			93,488				277,405
Convertible notes payable, net of discount of $3,118,819			1,103,959				558,668
Derivative liability			2,686,260				-
Contingent liability			52,749				61,767
Debentures, related parties			913,474				916,824
Due to related parties			458,266				533,001
Finance lease liability			8,907				11,744
Operating lease liability, current portion			413,506				415,392
Total current liabilities			10,915,511				7,904,858
Government loans and notes payable, net of current portion			63,777				65,038
Operating lease liability, net of current portion			1,585,667				1,693,577
Deferred tax liability			1,395,381				1,400,499
TOTAL LIABILITIES			13,960,336				11,063,972
Commitments and contingencies			-				-
STOCKHOLDERS’ EQUITY
Novo Integrated Sciences, Inc.
Convertible preferred stock; $0.001 par value; 1,000,000 shares authorized; 0 and 0 shares issued and outstanding at November 30, 2023 and August 31, 2023, respectively			-				-
Common stock; $0.001 par value; 499,000,000 shares authorized; 17,291,192 and 15,759,325 shares issued and outstanding at November 30, 2023 and August 31, 2023, respectively			17,292				15,760
Additional paid-in capital			95,481,354				90,973,316
Common stock to be issued (17,375 and 91,138 shares at November 30, 2023 and August 31, 2023)			44,443				1,217,293
Other comprehensive loss			(246,488	)			(357,383	)
Accumulated deficit			(71,713,384	)			(67,033,041	)
Total Novo Integrated Sciences, Inc. stockholders’ equity			23,583,217				24,815,945
Noncontrolling interest			(299,169	)			(316,870	)
Total stockholders’ equity			23,284,048				24,499,075
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY		$	37,244,384			$	35,563,047
* The condensed consolidated balance sheets’ common stock amounts have been retroactively adjusted to account for the Company’s 1:10 reverse stock split, effective November 7, 2023.
The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

NOVO INTEGRATED SCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
For the Three Months Ended November 30, 2023 and 2022 (unaudited)
		Three Months Ended
		November 30,				November 30,
		2023				2022
Revenues		$	3,891,218			$	3,419,280
Cost of revenues			1,947,200				1,679,747
Gross profit			1,944,018				1,739,533
Operating expenses:
Selling expenses			9,586				7,332
General and administrative expenses			5,252,069				3,974,161
Total operating expenses			5,261,655				3,981,493
Loss from operations			(3,317,637	)			(2,241,960	)
Non-operating income (expense)
Interest income			2,219				2,281
Interest expense			(143,374	)			(167,243	)
Other expense			(652,174	)			-
Change in fair value of derivative liability			585,529				-
Amortization of debt discount			(1,075,928	)			(1,490,513	)
Foreign currency transaction losses			(59,358	)			(39,301	)
Total non-operating expense			(1,343,086	)			(1,694,776	)
Loss before income taxes			(4,660,723	)			(3,936,736	)
Income tax expense			-				-
Net loss		$	(4,660,723	)		$	(3,936,736	)
Net income (loss) attributed to noncontrolling interest			19,620				(1,323	)
Net loss attributed to Novo Integrated Sciences, Inc.		$	(4,680,343	)		$	(3,935,413	)
Comprehensive loss:
Net loss			(4,660,723	)			(3,936,736	)
Foreign currency translation gain (loss)			108,976				(420,982	)
Comprehensive loss:		$	(4,551,747	)		$	(4,357,718	)
Weighted average common shares outstanding - basic and diluted			16,726,308				3,385,508
Net loss per common share - basic and diluted		$	(0.28	)		$	(1.16	)
* The condensed consolidated statements of operations and comprehensive loss’s share and per share amounts have been retroactively adjusted to account for the Company’s 1:10 reverse stock split, effective November 7, 2023.
The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

NOVO INTEGRATED SCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
For the Three Months Ended November 30, 2023 and 2022 (unaudited)
		Common Stock								Additional Paid-in				Common Stock To				Other Comprehensive				Accumulated				Total Novo Stockholders’				Noncontrolling				Total
		Shares				Amount				Capital				Be Issued				(Loss) Income				Deficit				Equity				Interest				Equity
Balance, August 31, 2023			15,759,325			$	15,760			$	90,973,316			$	1,217,293			$	(357,383	)		$	(67,033,041	)		$	24,815,945			$	(316,870	)		$	24,499,075
Cashless exercise of warrants			245,802				246				1,323,152				-				-				-				1,323,398				-				1,323,398
Exercise of warrants for cash			240,400				240				240,160				-				-				-				240,400				-				240,400
Share issuance for convertible debt settlement			519,845				520				577,002				-				-				-				577,522				-				577,522
Issuance of common stock to be issued			73,767				74				1,172,776				(1,172,850	)			-				-				-				-				-
Common stock issued for services			424,080				424				1,194,976				-				-				-				1,195,400				-				1,195,400
Rounding due to stock split			27,973				28				(28	)			-				-				-				-				-				-
Foreign currency translation gain			-				-				-				-				110,895				-				110,895				(1,919	)			108,976
Net (loss) income			-				-				-				-				-				(4,680,343	)			(4,680,343	)			19,620				(4,660,723	)
Balance, November 30, 2023			17,291,192			$	17,292			$	95,481,354			$	44,443			$	(246,488	)		$	(71,713,384	)		$	23,583,217			$	(299,169	)		$	23,284,048
Balance, August 31, 2022			3,118,063			$	3,118			$	66,084,887			$	9,474,807			$	560,836			$	(53,818,489	)		$	22,305,159			$	(257,588	)		$	22,047,571
Units issued for cash, net of offering costs			400,000				400				1,794,600				-				-				-				1,795,000				-				1,795,000
Issuance of common stock to be issued			3,623				4				92,362				(92,366	)			-				-				-				-				-
Cashless exercise of warrants			467,399				467				1,138,583				-				-				-				1,139,050				-				1,139,050
Fair value of stock options			-				-				60,887				-				-				-				60,887				-				60,887
Foreign currency translation loss			-				-				-				-				(417,008	)			-				(417,008	)			(3,974	)			(420,982	)
Net loss			-				-				-				-				-				(3,935,413	)			(3,935,413	)			(1,323	)			(3,936,736	)
Balance, November 30, 2022			3,989,085			$	3,989			$	69,171,319			$	9,382,441			$	143,828			$	(57,753,902	)		$	20,947,675			$	(262,885	)		$	20,684,790
* The condensed consolidated statements of stockholders’ equity share amounts have been retroactively adjusted to account for the Company’s 1:10 reverse stock split, effective November 7, 2023.
The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

NOVO INTEGRATED SCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Three Months Ended November 30, 2023 and 2022 (unaudited)
		Three Months Ended
		November 30,				November 30,
		2023				2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss		$	(4,660,723	)		$	(3,936,736	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization			572,404				586,166
Fair value of vested stock options			-				60,887
Financing costs for debt extension			1,323,398				1,139,050
Common stock issued for services			1,195,400				-
Operating lease expense			149,877				209,846
Amortization of debt discount			1,075,928				1,490,513
Foreign currency transaction losses			59,358				39,301
Change in fair value of derivative liability			(585,529	)			-
Changes in operating assets and liabilities:
Accounts receivable			(1,168,350	)			28,174
Inventory			(166,476	)			(157,118	)
Prepaid expenses and other current assets			130,584				1,471
Accounts payable			(98,996	)			321,961
Accrued expenses			71,214				149,945
Accrued interest			99,430				(9,232	)
Operating lease liability			(149,877	)			(202,465	)
Net cash used in operating activities			(2,152,358	)			(278,237	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayments to related parties			(72,402	)			(48,480	)
Repayments of notes payable			(183,100	)			-
Repayments of finance leases			(2,779	)			(2,763	)
Proceeds from issuance of convertible notes			3,314,153				-
Repayment of convertible notes			-				(2,777,778	)
Proceeds from the sale of units, net of offering costs			-				1,795,000
Proceeds from exercise of warrants			240,400				-
Net cash provided by (used in) financing activities			3,296,272				(1,034,021	)
Effect of exchange rate changes on cash and cash equivalents			79,770				12,271
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS			1,223,684				(1,299,987	)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD			416,323				2,178,687
CASH AND CASH EQUIVALENTS, END OF PERIOD		$	1,640,007			$	878,700
CASH PAID FOR:
Interest		$	45,321			$	186,911
Income taxes		$	-			$	-
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES:
Debt discount recognized on derivative liability		$	3,071,653			$	1,390,380
Common stock issued for convertible debt settlement		$	577,522			$	-
Debt discount recognized on convertible note		$	3,735,414			$	-
The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240122216090/en/

Chris David, COO-President

Novo Integrated Sciences, Inc.

chris.david@novointegrated.com

(888) 512-1195

Source: Novo Integrated Sciences, Inc.

FAQ

What are Novo Integrated Sciences, Inc.'s financial results for the first fiscal quarter ended November 30, 2023?

The company reported cash and cash equivalents of $1,640,007, total assets of $37,244,384, total liabilities of $13,960,336, and stockholders' equity of $23,284,048. Revenues were $3,891,218, representing a 14% increase from the same period in 2022.

What were Novo Integrated Sciences, Inc.'s revenue sources for the three months ended November 30, 2023?

Acenzia’s and Terragenx’s revenue for the three months ended November 30, 2023 were $1,683,850 and $16,971, respectively. Revenue from healthcare services increased by 1.2% compared to the same period in 2022.

What were Novo Integrated Sciences, Inc.'s operating costs for the three months ended November 30, 2023?

Operating costs were $5,261,655, representing a 32% increase from the same period in 2022, primarily due to common stock issuance for services and cashless warrant exercise.

What was Novo Integrated Sciences, Inc.'s net loss for the three months ended November 30, 2023?

The net loss attributed to the Company was $4,680,343, representing a 19% increase from the same period in 2022, mainly due to the increase in operating expenses.

What were Novo Integrated Sciences, Inc.'s major corporate and operational highlights for the three months ended November 30, 2023?

The company effectuated a 1-for-10 reverse stock split, entered into a Purchase and Sale Agreement for the Ophir Collection, and regained compliance with Nasdaq's minimum bid price requirement.